A Case Series of Culturally-adapted CBTp for Black People in the UK
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age16+
SponsorUniversity of Manchester
About this trial
The goal of this case series study is to learn if culturally-adapted cognitive-behavioural therapy is practical, acceptable and safe among Black Sub-Saharan African and Caribbean people experiencing psychosis. The main question it aims to answer is:
Is culturally-adapted CBT for psychosis feasible, acceptable to and safe for Black Sub-Saharan African and Caribbean people experiencing psychosis?
Participants will be asked to:
* Answer some questionnaires about how things are at the moment * Attend up to 16 sessions of therapy * Answer the same questionnaires to see what has changed, if anything * Complete a semi-structured interview about their expectations and experience of therapy
Eligibility criteria
Qualifiers
Service users who identify as Black British, Black Caribbean, Black African, African-Caribbean or Mixed African/Caribbean with at least one parent and/or grandparent born in a Sub-Saharan African or Caribbean country
People with a current ICD-10 schizophrenia spectrum disorder diagnosis, or who are currently receiving or have received support from an Early Intervention in Psychosis team
16 years or older
Sufficient understanding of English to complete study measures and engage with CBTp
Disqualifiers
Current, primary diagnosis of substance use disorder
Organic aetiology of psychosis
Lacking capacity to provide full informed consent
Currently experiencing a mental health crisis (i.e., are open to a home-based treatment team; are currently under Section of the Mental Health Act or have been under Section in the past 3 months) or immediate high risk to self or others (i.e., current suicidal intent or plans; unmanaged and intense non-suicidal self-injury)
Trial design
Treatments tested in this trial
- Culturally-adapted cognitive-behavioural therapy
Treatment groups
6 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov